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Abstract:  The increasing incidence of thyroid cancer is associated with a higher number of advanced disease 
characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways 
involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to 
blockade the oncogenic kinases (BRAF V600E, RET/PTC) or signaling kinases [vascular endothelial growth factor 
receptor (VEGFR), platelet-derived growth factor receptors (PDGFR)] involved in cellular growth and proliferation. 
Some clinical trials have been conducted showing the ability of targeted therapies (sorafenib, sunitinib, axitinib, imanitib, 
vandetanib, pazopanib, gefitinib) in stabilizing the course of the disease. Until now, however, no consensus guidelines 
have been established for patient selection and more data on toxicities and side effects are needed to be collected.  
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INTRODUCTION 
  The incidence of thyroid carcinoma is rising faster than 
many other cancers, with the highest overall rate of increase 
in cancer deaths [1].  
  Differentiated thyroid cancer (DTC) is usually treated by 
total thyroidectomy followed by radioactive iodine (
131I) 
ablation and thyroid hormone suppression of serum thyroid 
stimulating hormone (TSH). While cure is generally 
attainable in well-differentiated thyroid cancers [papillary 
(PTC) and follicular (FTC) types], recurrence occurs in up to 
40% of patients [2]. In the course of the disease in about 5% 
of patients with thyroid cancer recurrence, the tumor 
becomes dedifferentiated (DeDTC) and unresponsive to 
131I
treatment [3], and it is usually accompanied by more 
aggressive growth and metastatic spread [4,5]. So the 
traditional therapeutic modalities of treatment lose their 
effectiveness.  
  Radiotherapy and chemotherapy are the most popular 
treatment options for advanced stages of DTC and medullary 
thyroid carcinoma (MTC), but they confer only a modest 
benefit on tumor burden and overall survival. Their use is 
also limited by their toxicities. Current treatment regimens 
for advanced thyroid cancer include bleomycin, doxorubicin, 
platinum-containing compounds or a combination of these 
agents.  
  Recent research in the field of the molecular mechanisms 
of thyroid cancer has underlined the role of oncogenic   
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kinases, in particular in metastatic thyroid cancer [6]. 
Because of the high incidence of thyroid cancer, this field 
has become a focus of effort for use of new targeted 
therapies, especially the new class of agents that inhibit 
kinases involved in signaling, cellular growth, and 
angiogenesis [6]. Most of the therapeutic agents being 
developed actually target both the oncogenic and the 
signaling pathways. 
MEDULLARY THYROID CANCER AND RET
  MTC is a rare tumor arising from neural crest-derived 
parafollicular C cells. Sporadic MTC is the most common 
form (70%). Hereditary MTC is associated with activating 
germline mutations of the RET proto-oncogene. Hereditary 
MTC manifests as part of the Multiple Endocrine Neoplasia 
Type 2 (MEN2) syndrome [7], transmitted as an autosomal 
dominant trait.  
 The  RET gene is located on chromosome 10q11.2 [8]. 
RET encodes a transmembrane receptor with an extracellular 
portion containing four calcium-dependent cell-adhesion 
domains that mediate the conformational properties needed 
to interact with ligands [9]. The extracellular portion of the 
receptor also contains multiple glycosylation sites and a 
cysteine-rich region necessary for the tertiary structure of the 
protein and for receptor dimerization [10]. The intracellular 
domain of the RET receptor contains two tyrosine kinase 
regions that activate intracellular signal transduction 
pathways. RET activation triggers autophosphorylation of 
tyrosine residues, that serve as docking sites for adaptor 
proteins, which coordinate cellular signal transduction 
pathways (e.g., mitogen-activated protein kinase, 
phosphatidylinositol 3-kinase, AKT, Jun N-terminal kinase, 
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important in the regulation of cell growth [10]. The 
mutations of the RET gene in MTC lead to an activation of 
RET. 
  MEN2A is the most common (50%) form of hereditary 
MTC. There are three variants of MEN2A. The first is 
associated with Hirschsprung disease [11], the second is 
associated with cutaneous lichen amyloidosis [12] while the 
third variant, familial MTC (FMTC) [13] is characterized by 
MTC but no other manifestations of MEN2. MEN2A is 
characterized by bilateral, multicentric MTC in more than 
90% of index patients (carrying germline RET mutations in 
codon 634; i.e. those presenting with MTC at diagnosis in 
the absence of screening), pheochromocytomas in 50% and 
primary hyperparathyroidism in 10 to 20%. 
  MEN2B is less common than MEN2A (approximately 
20% of cases of MEN2) [14]. MEN2B is characterized by 
MTC in 100% of carriers, pheochromocytomas in 50%, 
mucosal ganglioneuromas in more than 90%, and a 
marphanoid habitus in nearly all. Early identification of 
MTC in MEN2B is important because metastases have been 
described during the first year of life. 
  The only possible curative treatment against MTC is its 
complete surgical resection, when possible [15]. Metastatic 
MTC patients are incurable because the cancer does not 
respond to radiotherapy or chemotherapy. The identification 
of activating mutations of the RET tyrosine kinase receptor 
in both hereditary and sporadic MTC makes this malignancy 
an excellent model to examine the effect of a group of small 
organic molecule tyrosine kinase inhibitors (TKIs) for the 
treatment of metastatic MTC. 
OVERVIEW ON MOLECULAR PATHWAYS 
INVOLVED IN THYROID CANCER DERIVED FROM 
FOLLICULAR CELLS 
  Of prime importance has been recognition of key 
oncogenic mutations in DTC and DeDTC. BRAF and RAS
genes code for kinases that activate signaling through the 
mitogen activated protein kinase (MAPK) pathway, 
regulating growth and function in both normal and neoplastic 
cells. Several tumor models support the evidence that most 
of the DTCs may be due to single activating somatic 
mutations in one of three genes: BRAF, RAS and 
traslocations producing RET/PTC oncogenes [5]. Molecular 
signaling pathways are differently affected in different types 
of thyroid cancer [6]. For example, BRAF mutation is found 
preferentially in PTC conventional variant. The substitution 
of a thymidine to adenine in exon 15 results in an amino acid 
sequence change of valine to glutamate (V600E); this 
alteration makes BRAF constitutively active [16,17,18] with 
a higher affinity for MEK1 and MEK2 and with a potent 
activating effect on MAPK pathway. This mutation (V600E) 
does not seem related to radiation exposure, but some 
authors suggest that PTCs with BRAF mutations are 
associated with a more aggressive clinical pattern, advanced 
stage and extrathyroidal invasion [19]. Furthermore, BRAF
mutation is common in aggressive microcarcinomas [20]; it 
is also correlated to a decreased expression of sodium-iodide 
symporter and so to the refractoriness to radioiodine therapy 
[21]. 
 In  DeDTC,  RET/PTC rearrangements are found in 30–
40%, RAS mutations in about 10%, and BRAF mutations in 
approximately 40–50%, with no overlap among these 
mutations in PTC, whereas a higher prevalence of BRAF
mutations (up to 70%) has been observed in dedifferentiated 
papillary thyroid carcinoma (DePTC) [5,22,23]. RET/PTC
rearrangements are correlated to radiation exposure and are 
found in pediatric PTC [24]. Twelve variants of RET/PTC
have been decribed [25]. More recently, it has been stressed 
the relevance of alterations in the PI3K/AKT pathway in the 
mechanism of tumorigenesis and of dedifferentiation, 
particularly in follicular variant cancer [26]. Alterations in 
this signaling pathway were found in 31% of benign thyroid 
adenoma, 24% of PTCs, 55% of FTCs and 58% of anaplastic 
thyroid cancer (ATC), underlining its important role in the 
progression of benign lesion toward ATC [27]. 
NEW AGENTS FOR THE TREATMENT OF 
THYROID CANCER: TKIS 
  Since 2005, a wide variety of multitargeted kinase 
inhibitors have entered clinical trials for patients with 
advanced or progressing metastatic thyroid cancers yielding 
higher response rates than cytotoxic chemotherapy, also if 
responses have been observed in only few patients [28]. 
Most of these agents have a common property of inhibiting 
vascular endothelial growth factor receptors (VEGFR), with 
a potent antiangiogenetic role, because of the structural 
similarity between RET and VEGFR kinases; i.e. Sorafenib 
has RAF-RET, and VEGFR-inhibiting activity; axitinib has 
VEGFR-, C-KIT-, and platelet-derived growth factor 
receptors (PDGFR)-inhibiting activity; pazopanib is an 
inhibitor of VEGFR and PDGFR; and sunitinib inhibits 
E7080 (a multi-kinase inhibitor) and VEGFR. 
  The toxicities (adverse effects) of these drugs differ 
slightly from the toxicities of mainstream anticancer drugs 
and they primarily consist of fatigue, hypertension, appetite 
loss, diarrhea, hypothyroidism and skin disease. Cases of 
hypothyroidism and severe cardiac impairment during TKIs 
therapy have been also described [29]. Because of the 
targeting similarities of many of TKIs, common toxicities 
exist among these agents [30]. 
  Since these drugs are basically administered long-term, 
their anti-tumor effect decreases greatly when the dose must 
be reduced or administration must be discontinued because 
of such adverse effects. 
  The effects of these new therapies seem to be more 
potent in patients with PTC than with FTC or poorly 
differentiated carcinoma, in those with the mutated BRAF
gene than with wild-type BRAF, and in those with lung 
rather than bone metastases [28]. 
  Several phase II trials of different tirosine kinases 
inhibitor were conducted and others are ongoing (Table 1).  
  There have been three different phase II trials of 
sorafenib [BAY 43-9006, 400 mg bis in die (b.i.d.)]. The 
first trial of sorafenib (400 mg b.i.d.) was conducted on 30 
DTC patients, and a partial response was reported in 7 
patients and stable disease in 16 patients [31]. The second 
trial reported a partial response in 6 patients and stable 
disease for 6 months or more in 23 of the 41 patients with 628 Current Genomics, 2011, Vol. 12, No. 8 Antonelli et al.
PTC, but therapy was ineffective in the 11 patients with FTC 
or poorly differentiated DTC and in the 4 patients with ATC 
[32]. In the third trial, which was conducted on 32 DTC 
patients, a partial response was reported in 8 patients and 
stable disease in 11 patients [33]. Greater efficacy of 
sorafenib was seen in PTC especially PTC with a BRAF
mutation, than in poorly differentiated DTC, and it had no 
effect on iodine uptake. A phase III trial comparing 
progression-free survival is under way in which sorafenib 
and placebo are being administered to patients with 
radioiodine resistant metastatic DTC.  
  On the other hand, several phase II trials of sunitinib 
(SU11248) are in progress and, according to the reports, thus 
far partial responses and stable diseases have been seen in 
DTC and MTC [34]. Carr et al. conducted a phase II study of 
continuous dosing of sunitinib in 35 patients affected by 
iodine-refractory DTC and MTC. Thirty three patients were 
evaluated for disease response according to RECIST: 1 
complete response, 10 partial response and 16 stable disease 
patients were observed [35]. Progressive disease was seen in 
6 patients [35]. 
 Cohen  et al. tested axitinib (starting dose, 5 mg twice 
daily) in sixty patients with advanced thyroid cancer of any 
histology. Responses were noted in all histologic subtypes. A 
partial response was observed in 18 patients and stable 
disease in another 23 patients [36]. 
 Recently,  Verbeek  et al. [37] compared the effect of four 
TKIs (axitinib, sunitinib, vandetanib and XL184) on cell 
proliferation, RET expression and autophosphorylation and 
extracellular signal-regulated kinases (ERK) activation in 
cell lines expressing a MEN2A, MEN2B mutations and a 
RET/PTC rearrangement, showing a most potent effect of 
XL184 (an inhibitor of VEGF receptors 1 and 2, C-MET, 
RET, C-KIT, FLT3, and Tie-2 [38]) in MEN2A and PTC 
and a more effective action of vandetanib in MEN2B in
vitro.
Table 1.  Clinical Trials with Targeted Therapies in Patients with Thyroid Cancer 
Author and year of the 
study 
Drug  Pathway inhibited  Thyroid cancer  Responses 
Gupta-Abramson et al.
2008
Sorafenib  RAF, RET, VEGFR  30 DTC  7 (23%)PR;  
16 (53%)SD  
(DTC) 
Kloos et al. 2009  Sorafenib  RAF, RET, VEGFR  41 PTC 
11 FTC 
4 ATC 
6 (15%)PR;  
23 (56%)SD (PTC) 
No response (FTC) 
No response (ATC) 
Hoftijzer et al. 2009  Sorafenib  RAF, RET, VEGFR  32 DTC  8 (25%)PR;  
11 (34%)SD (DTC) 
Cohen et al. 2008  Sunitinib E7080, VEGFR  37 DTC 
6 MTC 
4 (11%)PR; 21 (57%)SD 
(DTC) 
2 (33%)SD (MTC) 
Carr et al. 2010  Sunitinib E7080, VEGFR  28 DTC 
7 MTC 
1 (3%)CR 
10 (29%)PR 
16 (46%)SD 
Cohen et al. 2008  Axitinib  VEGFR, C-KIT, PDGFR  60 pts of any histology  18 (30%)PR, 23 (28%)SD 
de Groot 2007  Imatinib  VEGFR 2, RET  15 MTC  4 (27%)SD (MTC) 
Wells et al. 2010  Vandetanib  VEGFR 2, EGFR, RET  30 MTC hereditary  6 (20%)PR,  
16 (53%)SD (MTC) 
Robinson et al. 2010  Vandetanib  VEGFR 2, EGFR, RET  19 MTC hereditary  3 (16%)PR,  
10 (53%)SD (MTC) 
Bible et al. 2010  Pazopanib  VEGFR, PDGFR  39 DeDTC  18 (46%) PR (DeDTC) 
Pennel et al. 2008 Gefitinib  EGFR  27 patients of different 
tumor types 
No response  
VEGFR = vascular endothelial growth factor receptor; PDGFR = platelet-derived growth factor receptors; EGFR = epidermal growth factor receptor. 
DTC = differentiated thyroid cancer; ATC = anaplastic thyroid cancer; PTC = papillary thyroid cancer; FTC = follicular thyroid cancer; DeDTC = dedifferentiated differentiated 
thyroid cancer; MTC = medullary thyroid carcinoma.  
PR = partial response; SD = stable disease; CR = complete response. Targeted Therapies in Anaplastic Thyroid Cancer  Current Genomics, 2011, Vol. 12, No. 8    629
  The TKI imatinib (STI571) was tested in patients with 
metastatic MTC yelding no objective responses but stable 
disease in a minority of patients [39], while motesanib, in a 
mouse model of MTC, inhibited tumor xenograft growth 
reducing directly VEGFR 2 and RET expression [40].  
  A phase II study assessed the efficacy of Vandetanib 
(300 mg/day), a selective inhibitor of VEGFR2, epidermal 
growth factor receptor (EGFR) and RET, in patients with 
advanced hereditary MTC. Thirty patients were enrolled: 
20% of patients had a partial response, while an addictional 
53% of patients experienced a stable disease at 24 weeks. A 
reduction in calcitonin and carcinoembryonic antigen levels 
was also reported [41]. Another study evaluated vandetanib 
in 19 patients with advanced hereditary MTC, yielding a 
partial response in 3 patients, stable disease lasting 24 weeks 
or longer in further 10 patients with decreasing levels of 
calcitonin and carcinoembryonic antigen levels (a sustained 
50% or greater decrease from baseline in 3 of 19 patients and 
5% in 1 of 19 patients, respectively) [42].  
  Pazopanib (800 mg daily in 4-week cycles), an inhibitor 
of VEGFR and PDGFR, was tested in patients with 
metastatic, rapidly progressive and radioiodine refractory 
DTC and it seems to represent a promising therapeutic 
option (confirmed partial response in 18 patients of the 39 
enrolled) [43]. 
  A phase II trial of gefitinib (250 mg/day) has been 
performed in 27 patients [subtypes of thyroid cancer 
included: papillary (n=11), follicular (n=6), anaplastic (n=5), 
medullary (n=4), and Hurthle cell carcinomas (n=1)], but no 
antitumor effect was observed [44]. Gefitinib and vandetanib 
were tested in three thyroid cancer cell lines (ATC, FTC and 
PTC) and resulted as a potent inhibitors of EGF-R and 
VEGF-R with consequently reduction in cell proliferation 
and VEGF secretion [45]. 
  In a metastatic murine model of MTC, it has been 
recently tested a novel RET inhibitor, withaferin A, that was 
responsible for tumor regression and growth delay [46].  
TARGETED THERAPIES LIMITS AND SIDE 
EFFECTS 
  Tumor cells often devise strategies to bypass the effects 
of antineoplastic agents and selection of therapy-resistant 
clones is frequently the reason for treatment failure. 
  Imatinib treated chronic myeloid leukemia patients 
relapse is due to accumulation of very specific point 
mutations within the catalytic domain of the ABL kinase 
[47].  
  A lack of response can occur, for instance, because target 
inhibition raises the activity of compensatory signal 
pathways, which, in turn, rescue tumor cell growth. 
However, the possibility of testing the sensitivity of primary 
DePTC cells from each subject to different TKIs could 
increase the effectiveness of the treatment. In fact, in vitro
chemosensitivity tests are able to predict in vivo
effectiveness in 60% of cases [48]; while, it is well known 
that a negative chemosensitivity test in vitro is associated 
with a 90% of ineffectiveness of the treatment in vivo [47], 
allowing the administration of inactive chemotherapeutics to 
these patients to be avoided [48]. It has been recently 
demonstrated that it is possible to test the antineoplastic 
activity of different compounds [antiblastics or peroxisome 
proliferator-activated receptor (PPAR)- agonists] in primary 
anaplastic thyroid cancer cells obtained from each patient 
[49, 50]. Furthermore, it has been shown that primary cells 
can be obtained directly from fine needle aspiration samples 
of thyroid cancer, and that the results of in vitro
chemosensitivity tests are quite similar to those obtained 
from surgical biopsies [51]. Interestingly, more recently, we 
have first shown an antitumoral effect of two new multi-
targeted kinases inhibitors (CLM3 and CLM29) not on 
continuous cell lines, that are quite different from the tumor 
of the patients themselves, but directly on primary DePTC of 
patients refractory to the radioiodine therapy [52], opening 
the way to the possibility of personalizing the kinase 
inhibitors therapy in each patient.  
  Numerous side effects of the multi-targeted kinases 
inhibitors were reported; in different trials, several patients 
required a dose reduction to improve tolerability. The most 
common side effects involved cardiovascular system 
(hypertension, cardiomyopathy, stroke) and skin (rashes, 
foot and hand syndrome) [28]. Some cases of TSH elevation 
were also observed, especially during motesanib therapy 
[53].  
CONCLUSION 
  The most encouraging results, in patients with advanced 
DTC and DeDTC unresponsive to radioiodine therapy and 
MTC, were obtained with the targeted kinase inhibitors with 
an intrinsic activity against VEGFR and cross activity 
against RET kinases, such as pazopanib, sorafenib, 
motesanib, sunitib and vandetanib. Also axitinib, a more 
specific inhibitor of VEGFR, showed a great efficacy [36]. 
Unfortunately, eventual progression despite antiangiogenic 
VEGFR blockade suggests emergence of alternate pathways 
to promote tumor growth and metastasis (including FGFR, 
C-MET, and angiopoietins) [54]. 
  Until now, no consensus guidelines or standard criteria 
for patients enrolling were established definitively. Thereby 
the effects on survival are unclear, because of lack of 
complete responses and because of the discrepancies 
between the radiographic tumor responses and the effective 
improvement of survival [30]. 
  The aim of the introduction of these targeted therapies is 
to extend life duration assuring a good quality of life. To 
reach these goals, we need to have further data on toxicities 
of single agent and of combination of more drugs, to identify 
specific biomarkers able to predict the treatment efficacy, the 
clinical outcome and to guarantee a tailored dosage of the 
drugs. Moreover, the possibility to test in vitro (in primary 
thyroid cancer cells) these novel drugs may help to improve 
further the personalization of the treatment.  
ABBREVIATIONS 
ATC =  Anaplastic  thyroid  cancer 
b.i.d. =  Bis  in  die 
CR  =  Complete response  
DeDTC  =  Dedifferentiated differentiated thyroid cancer 630 Current Genomics, 2011, Vol. 12, No. 8 Antonelli et al.
DePTC  =  Dedifferentiated papillary thyroid carcinoma 
DTC =  Differentiated  thyroid  cancer 
EGFR  =  Epidermal growth factor receptor 
ERK  =  Extracellular signal-regulated kinases 
FMTC  =  Familial medullary thyroid carcinoma 
FTC  =  Follicular thyroid cancer 
MAPK  =  Mitogen activated protein kinase 
MEN2  =  Multiple Endocrine Neoplasia Type 2  
MTC =  Medullary  thyroid  carcinoma 
PDGFR  =  Platelet-derived growth factor receptors 
(PPAR)-  =  Peroxisome proliferator-activated receptor-
PR =  Partial  response 
PTC  =  Papillary thyroid cancer 
SD =  Stable  disease 
TKIs =  Tyrosine  kinase  inhibitors 
TSH =  Thyroid-stimulating  hormone 
VEGFR  =  Vascular endothelial growth factor receptor 
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